NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Post Marketing Surveillance Study to Observe Safety and Efficacy of Inlyta in South Korea

CompletedN/A

Sponsor: Pfizer

Conditions: Advanced Renal Cell Carcinoma

Interventions: Axitinib

Countries: South Korea

The objective of this study is to monitor the usage of INLYTA® in real practice, including the adverse events associated with INLYTA®.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Patients diagnosed as advanced RCC after failure of one prior systemic therapy.

Exclusion Criteria:

* Any patient who does not agree that Pfizer or companies working on behalf of Pfizer can use his/her information.
* Patients with hypersensitivity to axitinib or to any other component of INLYTA® .
* Patients under 18.
* Pregnant women.

Locations (1)

Seoul, South Korea